Kazia therapeutics (kzia): paxalisib chinese rights licensed

London, uk / accesswire / march 30, 2021 / kazia (nasdaq:kzia) has announced it has signed an agreement for the greater china rights to paxalisib with simcere pharmaceuticals. the deal includes an us$11m upfront (us$7m in cash, and us$4m in an equity investment), up to us$281m in milestone payments and royalties in the mid-teens.
KZIA Ratings Summary
KZIA Quant Ranking